Atara Biotherapeutics Statistics
Share Statistics
Atara Biotherapeutics has 5.96M
shares outstanding. The number of shares has increased by 19.47%
in one year.
| Shares Outstanding | 5.96M |
| Shares Change (YoY) | 19.47% |
| Shares Change (QoQ) | 1.72% |
| Owned by Institutions (%) | 21.92% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 750 |
| FTD / Avg. Volume | 1.28% |
Short Selling Information
The latest short interest is 522.14K, so 8.91% of the outstanding
shares have been sold short.
| Short Interest | 522.14K |
| Short % of Shares Out | 8.91% |
| Short % of Float | 9.02% |
| Short Ratio (days to cover) | 13.38 |
Valuation Ratios
The PE ratio is -1.17 and the forward
PE ratio is -3.05.
Atara Biotherapeutics's PEG ratio is
0.01.
| PE Ratio | -1.17 |
| Forward PE | -3.05 |
| PS Ratio | 0.77 |
| Forward PS | 0.2 |
| PB Ratio | -1.02 |
| P/FCF Ratio | -1.45 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Atara Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48,
with a Debt / Equity ratio of -0.45.
| Current Ratio | 0.48 |
| Quick Ratio | 0.4 |
| Debt / Equity | -0.45 |
| Debt / EBITDA | -0.58 |
| Debt / FCF | -0.64 |
| Interest Coverage | -18.08 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $842,745.1 |
| Profits Per Employee | $-558,189.54 |
| Employee Count | 153 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 1.97 |
Taxes
| Income Tax | -12K |
| Effective Tax Rate | 0.01% |
Stock Price Statistics
The stock price has increased by -56.31% in the
last 52 weeks. The beta is 0.3, so Atara Biotherapeutics's
price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | -56.31% |
| 50-Day Moving Average | 6.7 |
| 200-Day Moving Average | 8.85 |
| Relative Strength Index (RSI) | 46.63 |
| Average Volume (20 Days) | 58,483 |
Income Statement
In the last 12 months, Atara Biotherapeutics had revenue of 128.94M
and earned -85.4M
in profits. Earnings per share was -11.41.
| Revenue | 128.94M |
| Gross Profit | 107.93M |
| Operating Income | -83.44M |
| Net Income | -85.4M |
| EBITDA | -75.75M |
| EBIT | -80.8M |
| Earnings Per Share (EPS) | -11.41 |
Full Income StatementBalance Sheet
The company has 25.03M in cash and 43.83M in
debt, giving a net cash position of -18.8M.
| Cash & Cash Equivalents | 25.03M |
| Total Debt | 43.83M |
| Net Cash | -18.8M |
| Retained Earnings | -2.05B |
| Total Assets | 109.1M |
| Working Capital | -69.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -68.72M
and capital expenditures -246K, giving a free cash flow of -68.96M.
| Operating Cash Flow | -68.72M |
| Capital Expenditures | -246K |
| Free Cash Flow | -68.96M |
| FCF Per Share | -9.21 |
Full Cash Flow StatementMargins
Gross margin is 83.71%, with operating and profit margins of -64.71% and -66.23%.
| Gross Margin | 83.71% |
| Operating Margin | -64.71% |
| Pretax Margin | -66.24% |
| Profit Margin | -66.23% |
| EBITDA Margin | -58.75% |
| EBIT Margin | -64.71% |
| FCF Margin | -53.48% |
